July 1st, 2020

// Mitsubishi Tanabe Pharma Canada Announces that Manitoba has Added the Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) to its Provincial Drug Formulary

Mitsubishi Tanabe Pharma Canada Announces that Manitoba has Added the Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) to its Provincial Drug Formulary

TORONTO, June 30, 2020 /CNW/ – Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA), a subsidiary of Mitsubishi Tanabe Pharma America, Inc. (MTPA), announced today that RADICAVA® (edaravone), an infusion treatment for amyotrophic lateral sclerosis (ALS), has been added to the Manitoba Drug Benefits and Interchangeability Formulary (special authorization), and the listing will take effect on July 16.

“The listing of RADICAVA is encouraging news for the Manitoba ALS community,” said Atsushi Fujimoto, President, MTP-CA. “We thank the Government of Manitoba for providing eligible ALS patients access to the therapy and their ongoing commitment to those affected by ALS.” 

MTP-CA continues to have discussions with other provinces, territories and federal agencies regarding the listing of RADICAVA under additional publicly funded drug programs. In addition to the Manitoba Drug Benefits and Interchangeability Formulary (special authorization), RADICAVA also is listed on the: 

  • Régie de l’assurance maladie du Québec (RAMQ) formulary (special authorization); 
  • Ontario Drug Benefit Formulary (Exceptional Access Program); 
  • Alberta Drug Benefit List (special authorization); and 
  • New Brunswick Drug Plan (NBDP) formulary (special authorization).

RADICAVA is an intravenous infusion treatment for ALS, a rapidly progressive, neurodegenerative and fatal disease.1

About RADICAVA® (edaravone) 

RADICAVA (edaravone) is indicated to slow the loss of function in patients with amyotrophic lateral sclerosis (ALS), as measured by the ALS Functional Rating Scale – Revised (ALSFRS-R).Edaravone was discovered and developed for ALS by Mitsubishi Tanabe Pharma Corporation (MTPC) through an iterative clinical development platform over a 13-year period. In 2015, edaravone was approved for use as a treatment for ALS in Japan and South Korea. RADICAVA was approved by the U.S. Food and Drug Administration in May of 2017. Marketing authorization was granted in Canada in October 2018 and Switzerland in January 2019.

About Mitsubishi Tanabe Pharma Canada, Inc.

Based in Toronto, Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA) is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma America, Inc. (MTPA) with a goal to provide therapies for some of the most difficult-to-treat diseases, including ALS. For more information, please visit 

www.mt-pharma-ca.com.

About Mitsubishi Tanabe Pharma America, Inc.

Based in Jersey City, N.J., Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation’s (MTPC) 100 percent owned U.S. holding company, Mitsubishi Tanabe Pharma Holdings America, Inc. MTPA is dedicated to delivering innovative products that address the unmet medical needs of patients in North America. It was established by MTPC to commercialize approved pharmaceutical products in North America with plans to expand its product line through collaborations with partners. For more information, please visit www.mt-pharma-america.com.

___________________________
1National Institute of Neurological Disorders and Stroke. Amyotrophic Lateral Sclerosis (ALS) Information Page.
https://www.ninds.nih.gov/disorders/all-disorders/amyotrophic-lateral-sclerosis-als-information-page. Accessed March 2018.
2RADICAVA® (edaravone) Canada Product Monograph. October 2019. https://www.mt-pharma-ca.com/our-product/

SOURCE Mitsubishi Tanabe Pharma Canada, Inc.

Leave a Reply

Your email address will not be published. Required fields are marked *

TRAIN IT RIGHT NEWSLETTER

Sign Up and get a free 7 day Train it Right HIIT Program!

Top